News | May 30, 2025
Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Subscribe To Our Newsletter & Stay Updated
